Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Thurman Alex R., Senior Vice President and Chief Financial Officer of Glaukos Corp (NYSE:GKOS), recently executed multiple stock transactions, according to a recent SEC filing. On March 25, Alex R. sold shares totaling approximately $162,398, with sale prices ranging from $106.56 to $108.14 per share. The transactions occurred as the medical technology company, currently valued at $5.87 billion, trades near $103.62, with analyst targets ranging from $110 to $200 per share.
In addition to the sales, Alex R. had shares withheld for tax obligations upon the vesting of restricted stock units, totaling $503,734, with prices ranging from $96.60 to $107.61 per share. Following these transactions, Alex R. holds 53,431 shares of Glaukos Corp, including 19,387 restricted stock units that have not yet vested. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 5.99 and has achieved impressive revenue growth of 21.85% over the last twelve months.
These sales were conducted under a pre-established Rule 10b5-1 trading plan, adopted in December 2024, allowing insiders to sell stock at predetermined times to avoid potential conflicts of interest. InvestingPro analysis indicates the company maintains a FAIR financial health score, with additional insights available in the comprehensive Pro Research Report, one of 1,400+ detailed company analyses available to subscribers.
In other recent news, Glaukos Corporation reported its fourth-quarter 2024 earnings with a revenue of $105.5 million, surpassing analyst estimates of $100.53 million, marking a 28% year-over-year increase. Despite the revenue beat, the company’s earnings per share (EPS) came in at -$0.40, slightly missing the forecasted -$0.38. BTIG adjusted its price target for Glaukos to $155 from $157, maintaining a Buy rating, following the company’s financial performance. Meanwhile, Truist Securities continues to express confidence in Glaukos by maintaining a Buy rating with a price target of $185, highlighting the potential of the iDose product, which saw revenue double from $13 million to $16 million quarter-over-quarter.
The U.S. Food and Drug Administration (FDA) has set a review date for Glaukos’ new drug Epioxa, designed to treat keratoconus, with a decision expected by October 2025. This development follows positive results from two Phase 3 pivotal trials for Epioxa. Stifel also maintains a Buy rating on Glaukos, with a $175 price target, citing confidence in the iDose product despite recent challenges. The firm believes reimbursement hurdles are temporary and expects them to diminish over time.
Glaukos has provided guidance for 2025, projecting net sales between $475 million and $485 million, representing a growth of 24% to 26%. The company is also planning to launch several innovative products, including the iDose Trio, in 2026. Despite some headwinds, such as pressure on U.S. legacy glaucoma products and foreign exchange impacts, analysts remain optimistic about Glaukos’ growth trajectory, particularly with the potential of the iDose product.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.